Clearly those types of applications, particularly when they require Health Canada's oversight in terms of pre-approval before they get used, have been identified and are identified very early on in the process. Actually, at the pre-submission level, in discussions with industry in applying those recommendations, we would identify the potential public health benefit from the application, and it gets triaged into a high priority for the safety and efficacy assessment.
Now, depending on the type of the application, we may or may not require a regulatory amendment. In those modern technologies that Dr. Farber was mentioning--the ultra-high-pressure processes--they actually fit the definition of “novel processes”. Actually in that case, we have a modern regulation: it's the novel foods regulations, encompassing novel processes. Those processes are immediately identified as a priority. They do not need a regulatory amendment but we need to ascertain the safety and efficacy assessment, and then they get treated as a priority. A number of those were approved previously and also most recently. We encourage submissions from industry to have those technologies first approved, and then potentially taken up by industry.